Sources: Flock Safety is weighing a potential sale and has held preliminary talks with outside advisers
THE SO WHAT
A potential sale of Flock Safety under scrutiny for camera proliferation is a reminder that surveillance infra carries reputational and policy risk alongside growth. Cities and enterprises relying on similar systems should be documenting data retention, access, and exit plans before ownership changes hands.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureStartups Modal, Baseten in Funding Talks to Help Businesses Run AI
Infra platforms like Modal and Baseten doubling valuations this fast means investors are betting that “run and manage models” is a durable layer, not a feature. If you’re building on them, assume more product breadth and higher prices ahead — but also more leverage to avoid stitching your own infra.
Startups & VentureVC firm Bessemer now has another $5.75B to invest in (what else?) AI
Another $5.75B earmarked for AI from a top-tier VC means capital is still over-supplied relative to proven business models. Founders should expect aggressive term sheets but harsher scrutiny on defensibility — infra, data moats, and real unit economics — as funds try not to be the last money into me-too plays.
Startups & VentureTrump Jr.’s 1789 Capital in Talks to Raise $3 Billion in New Funds
A $3 billion target for a second growth fund is another data point that late-stage private capital is back for larger startup bets. Founders at Series C and beyond should expect more term sheet competition — but also more scrutiny on real unit economics, not just AI narrative.
Startups & VentureEnveda secures $311M to bring more nature-derived AI drugs into clinical trials
A $311 million round at a $2 billion valuation for AI-guided, nature-derived drugs shows investors are backing full-stack biotech, not just model vendors. Pharma and health systems should treat these players as future pipeline partners and start mapping overlap in indications now.